Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk (2015)
- Authors:
- Autor USP: REGO, EDUARDO MAGALHÃES - FMRP
- Unidade: FMRP
- DOI: 10.1093/annonc/mdv317
- Subjects: NEOPLASIAS; HEMATOLOGIA; RIM; ÁCIDO ÚRICO; DOENÇAS HEMATOLÓGICAS
- Language: Inglês
- Imprenta:
- Source:
- Título: Annals of Oncology
- ISSN: 0923-7534
- Volume/Número/Paginação/Ano: v. 26, n. 10, p. 2155-2161, 2015
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
- Licença: publisher-specific-oa
-
ABNT
SPINA, M. et al. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, v. 26, n. 10, p. 2155-2161, 2015Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdv317. Acesso em: 27 dez. 2025. -
APA
Spina, M., Nagy, Z., Ribera, J. M., Federico, M., Aurer, I., Jordan, K., et al. (2015). Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, 26( 10), 2155-2161. doi:10.1093/annonc/mdv317 -
NLM
Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [Internet]. Annals of Oncology. 2015 ; 26( 10): 2155-2161.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1093/annonc/mdv317 -
Vancouver
Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [Internet]. Annals of Oncology. 2015 ; 26( 10): 2155-2161.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1093/annonc/mdv317 - Trangenic mice expressing hCG-NuMA-RAR'alfa' develop hematopoietic abnormalities leading to acute promyelocytic leukemia
- Role od promyelocytic leukemia (PML) protein in tumor suppression
- Estudo da relevância da inativação do CCAAT enhancer binding protein 'alfa' (C/EBP'alfa') na gênese da leucemia promielocítica
- Linfomas não Hodgkin de células T maduras e de células NK extramodais
- Identification of myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia
- Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma
- Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia
- Anemia e palidez
- Temporal trends in Hematopoietic Stem Cell Transplantation in Argentina. [Editorial]: regional differences that mirror the global reality
- Tromboembolismo venoso
Informações sobre o DOI: 10.1093/annonc/mdv317 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
